vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Average Price Target of $55.83

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have received an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $55.83.

A number of research analysts have weighed in on the stock. BTIG Research lifted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. HC Wainwright cut their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Rodman & Renshaw began coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price on the stock. Finally, Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th.

vTv Therapeutics Price Performance

NASDAQ VTVT opened at $28.23 on Wednesday. The firm has a market capitalization of $111.23 million, a P/E ratio of -26.63 and a beta of 0.21. vTv Therapeutics has a 1-year low of $19.50 and a 1-year high of $44.00. The business’s 50-day simple moving average is $31.90 and its 200-day simple moving average is $33.55.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, equities research analysts expect that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.